- Home
- MRUS vs BLCO Comparison
MRUS vs BLCO Comparison
Compare MRUS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- BLCO
- Stock Information
- Founded
- MRUS 2003
- BLCO 1853
- Country
- MRUS Netherlands
- BLCO Canada
- Employees
- MRUS N/A
- BLCO N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- BLCO Ophthalmic Goods
- Sector
- MRUS Health Care
- BLCO Health Care
- Exchange
- MRUS Nasdaq
- BLCO Nasdaq
- Market Cap
- MRUS 5.1B
- BLCO 5.2B
- IPO Year
- MRUS 2016
- BLCO 2022
- Fundamental
- Price
- MRUS $94.81
- BLCO $15.47
- Analyst Decision
- MRUS Buy
- BLCO Hold
- Analyst Count
- MRUS 18
- BLCO 12
- Target Price
- MRUS $93.72
- BLCO $15.91
- AVG Volume (30 Days)
- MRUS 2.6M
- BLCO 437.2K
- Earning Date
- MRUS 10-31-2025
- BLCO 10-29-2025
- Dividend Yield
- MRUS N/A
- BLCO N/A
- EPS Growth
- MRUS N/A
- BLCO N/A
- EPS
- MRUS N/A
- BLCO N/A
- Revenue
- MRUS $56,228,000.00
- BLCO $4,976,000,000.00
- Revenue This Year
- MRUS $51.77
- BLCO $8.29
- Revenue Next Year
- MRUS N/A
- BLCO $5.82
- P/E Ratio
- MRUS N/A
- BLCO N/A
- Revenue Growth
- MRUS 59.77
- BLCO 6.23
- 52 Week Low
- MRUS $33.19
- BLCO $10.45
- 52 Week High
- MRUS $95.30
- BLCO $20.94
- Technical
- Relative Strength Index (RSI)
- MRUS 79.21
- BLCO 56.20
- Support Level
- MRUS $94.59
- BLCO $15.50
- Resistance Level
- MRUS $95.06
- BLCO $15.97
- Average True Range (ATR)
- MRUS 0.36
- BLCO 0.47
- MACD
- MRUS -1.00
- BLCO 0.02
- Stochastic Oscillator
- MRUS 47.87
- BLCO 76.29
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.